BIOM3
vs
B
BOVESPA
BIOM3
Over the past 12 months, BIOM3 has underperformed BOVESPA, delivering a return of -23% compared to the BOVESPA's +51% growth.
Stocks Performance
BIOM3 vs BOVESPA
Performance Gap
BIOM3 vs BOVESPA
Performance By Year
BIOM3 vs BOVESPA
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biomm SA
Glance View
BIOMM SA engages in the research, development, and manufacture of insulin. The company is headquartered in Nova Lima, Minas Gerais. The company went IPO on 2002-09-05. The firm is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Company’s technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Company’s technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Company’s subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
